Biopharma therapeutics and platform equity financing shifted decisively toward scale in Q2 2026. Deal counts held steady across all three channels while proceeds expanded sharply, concentrating capital into larger offerings rather than spreading it across more issuers.
IPO activity strengthened materially, with 10 companies raising $3.6B against 11 IPOs and $2.3B in Q1. Volume fell 9% while proceeds rose roughly 57%, lifting average proceeds per IPO from about $209M to $360M. First-half totals reached 21 IPOs and $5.9B. Prominent listings were upsized during marketing and priced at $18. Hemab Therapeutics expanded from 11.76 million shares to 19,262,500 and opened at $27, a 50% gain. Avalyn Pharma expanded from a $201M target to $345M. Odyssey Therapeutics upsized from 13.24 million shares and anchored its book with a $25M TPG Life Sciences Innovations placement, backed by $879M raised by immunology IPOs in 2026 against $174M in 2025.
Follow-ons supplied the quarter’s largest capital pool, with 40 issuances raising $11.9B against 38 issuances and $8.1B in Q1. Volume rose about 5% while capital grew nearly 47%, lifting average proceeds per issuance from roughly $213M to $298M. First-half totals reached 78 issuances and $20B. Data set the terms. Revolution Medicines raised $2.2B gross after RASolute 302 delivered a median OS of 13.2 months versus 6.7 months, with a hazard ratio of 0.40, pairing common stock with a 0.50% convertible struck at 40% above market. Definium Therapeutics priced $805 million on Emerge Phase 3 data showing an -8.1 point placebo-adjusted MADRS difference at Week 6. Cytokinetics took in $805 million after MYQORZO’s launch quarter, producing $5 million in revenue across an estimated 680 patients.
PIPE financing held stable, with 42 issuances raising $3.2B against 41 PIPEs and $2.9B in Q1. Volume rose about 2% and capital roughly 10%, lifting average deal size from around $71M to $76M. First-half totals reached 83 issuances and $6.1B. Terms reflected discipline rather than enthusiasm. Artiva Biotherapeutics raised $300M on a 71% ACR50 response in refractory rheumatoid arthritis at six months. Achieve Life Sciences structured up to $354M, with $180M upfront and $174M deferred into milestone-driven warrants, pricing one day after disclosing an Official Action Indicated classification at its manufacturer. Sagimet Biosciences raised $175M to fund a strategic narrowing into acne rather than an expansion.
Biopharma Therapeutics and Platforms IPO Activity
Biopharma therapeutics and platform IPO activity strengthened materially in Q2 2026, with 10 companies raising a combined $3.6B, compared with 11 IPOs raising $2.3B in Q1. While IPO volume declined by 9%, total proceeds increased by approximately 57%, reflecting larger offerings and stronger funding. Average proceeds per IPO rose from about $209M in Q1 to $360M in Q2. Across H1 of 2026, the sector completed 21 IPOs and raised $5.9B.
Prominent Biopharma Therapeutics and Platforms IPO Activity in Q2 2026
Hemab Therapeutics – IPO – $346.7M – April 2026
Hemab (Nasdaq: COAG) priced its upsized IPO on April 30, 2026, at $18 per share, selling 16,750,000 shares and closing on May 4 with 19,262,500 shares following full greenshoe exercise, for approximately $347M gross. Terms initially contemplated 11.76 million shares at $16.00 to $18.00; shares opened at $27, a 50% gain. Lead bispecific antibody sutacimig delivered annualized treated bleed-rate reductions of 19% to 87% and a 100% reduction in high-intensity bleeds, supporting a Phase 3 start in H2 2026. With $186M in year-end 2025 cash and full global rights retained, the principal risks are pipeline concentration and small diagnosed populations.
Avalyn Pharma – IPO – $345M – April 2026
Avalyn (Nasdaq: AVLN) priced on April 29, 2026, at $18 per share, raising $300M from 16,666,667 shares before closing on May 1 with 19,166,667 shares and $345M in proceeds. The offering expanded from an initial 11.8 million shares targeting roughly $201M. Its inhaled antifibrotic programs, AP01 and AP02, aim to improve local lung exposure while reducing systemic toxicity; AP01 is in global Phase 2b, and AP02 is in global Phase 2. Proceeds include roughly $150M for AP01, $90M for AP02, and $10M for AP03, supplementing $138M entering 2026.
Odyssey Therapeutics – IPO – $280M – April 2026
Odyssey (Nasdaq: ODTX) priced its IPO on May 7, 2026, at $18 per share, selling 15,500,000 shares and adding a 1,388,889-share private placement to TPG Life Sciences Innovations at the same price. The IPO raised $279M, with $25M raised privately; the deal was upsized from 13.24 million shares at $16 to $18 and closed May 11 after trading began May 8. OD-001 has Phase 2a proof-of-concept in ulcerative colitis, while OD-002 is in IND-enabling studies. Approximately $135M is allocated to OD-001, $50M to SLC15A4 development, and the company expects runway into H2 2028. The second IPO attempt follows a $213M series D, which was withdrawn five months after its January 2025 filing.
Biopharma Therapeutics and Platforms Follow-on Issuances
Biopharma therapeutics and platform follow-on financing activity strengthened in Q2 2026, with 40 issuances raising a combined $11.9B, compared with 38 issuances raising $8.1B in Q1. Transaction volume increased by only about 5%, while total capital raised grew by nearly 47%, indicating that companies completed larger financings during the quarter. Average proceeds per issuance rose from approximately $213M in Q1 to $298M in Q2. During the first half of 2026, the sector recorded 78 follow-on issuances and raised $20B, reflecting demand for equity financing.
Prominent Biopharma Therapeutics and Platforms Follow-on Issuances in Q2 2026
Revolution Medicines – Common – $1.724B – April 2026
Revolution Medicines (Nasdaq: RVMD) priced 10,563,381 shares at $142.00 on April 15, 2026, for roughly $1.5B, alongside $500M of 0.50% convertible senior notes due 2033. Both offerings were upsized from $750M and $250M, respectively. The transaction closed April 17 with 12,147,887 shares, including 1,584,506 greenshoe shares, generating $2.2B gross and approximately $2.1B net; the notes convert at roughly $198.80 per share. The financing followed Phase 3 RASolute 302 data showing median OS of 13.2 months versus 6.7 months for chemotherapy and a hazard ratio of 0.40 (p<0.0001). The 0.50% convertible, struck 40% above market, reduced blended financing costs and near-term dilution. With $2.1B net, the investment case now hinges on launch execution and expansion beyond pancreatic cancer rather than clinical validation alone.
Definium Therapeutics – Common – $805M – June 2026
Definium (Nasdaq: DFTX) priced 20,588,236 shares at $34 on June 23, 2026, raising approximately $700M before full exercise of the 3,088,235-share option on June 24 lifted gross proceeds to roughly $805M and net proceeds to $758M. The offering priced at a 6% discount to the $36.18 closing price and included a 60-day management lock-up. The financing followed Emerge Phase 3 data for a single 100 µg DT120 ODT dose: LS mean MADRS change at Week 6 was -13.3 versus -5.2 for placebo, an -8.1 point difference (p<0.0001), with placebo-adjusted reductions of -14.2 at Week 1 and -7.3 at Week 12. No serious adverse events or suicidality signal were reported among 149 participants at 20 sites. The company has four Phase 3 trials across GAD and MDD; key risks are replication, two GAD readouts, DEA scheduling, and functional unblinding.
Cytokinetics – Common – $805M – May 2026
Cytokinetics (Nasdaq: CYTK) priced 9,859,155 shares at $71.00 on May 6, 2026, for approximately $700M, upsized from $650M. Full exercise of the 1,478,873-share option brought the May 8 closing to 11,338,028 shares, roughly $805M gross, and $760M net. The raise followed MYQORZO’s January launch, with over 275 prescribers, an estimated 680 patients, and $5M in initial partial-quarter revenue, as well as positive ACACIA-HCM data and a November 14, 2026 PDUFA date. Cash totaled roughly $1.1B at March 31, and Germany launched June 1. Management raised equity after a 127% twelve-month return despite access to up to $175M in Royalty Pharma debt and $150M in optional trial funding; new investors absorbed $72.23 per share of immediate dilution.
Biopharma Therapeutics and Platforms PIPE Issuances
Biopharma therapeutics and platform PIPE financing remained stable in Q2 2026, with 42 issuances raising a combined $3.2B, compared with 41 PIPEs raising $2.9B in Q1. While transaction volume increased by only about 2%, total capital raised grew by approximately 10%, resulting in a modest increase in average deal size from around $71M in Q1 to $76M in Q2. During H1 of 2026, the sector completed 83 PIPE issuances and raised $6.1B.
Prominent Biopharma Therapeutics and Platforms PIPE Issuances in Q2 2026
Artiva Biotherapeutics – PIPE – $300M – May 2026
Artiva (Nasdaq: ARTV) priced 23,871,526 shares at $11.52 and pre-funded warrants for 2,170,138 shares on May 8, 2026, raising approximately $300M and closing May 11. This was an underwritten S-3 shelf offering, not a Section 4(a)(2) private placement. AlloNK produced a 71% ACR50 response in refractory rheumatoid arthritis at six months, with no relapses, new immunomodulatory treatment, CRS, ICANS, or discontinuations. More than 70 autoimmune patients have been treated across more than 40 primarily community sites, and the FDA aligned on a roughly 150-patient registrational trial. Artiva had $87M at March 31, funding operations into Q2 2027 before the financing; the registrational trial is planned for H2 2026.
Achieve Life Sciences – PIPE – $180M – April 2026
Achieve (Nasdaq: ACHV) announced a financing on April 16, 2026, of up to approximately $354M: $180M upfront and up to $174M from milestone-driven warrants. The April 17 transaction, structured at roughly $3.63 per unit, generated roughly $169M in net proceeds against a $29M March 31 cash balance. The company had disclosed an Official Action Indicated classification at its third-party manufacturer one day earlier; a Complete Response Letter arrived June 22, citing cGMP observations and incomplete labeling but no efficacy or safety deficiencies. Achieve plans a Q4 2026 resubmission with Adare Pharma Solutions and potential approval in H1 2027.
Sagimet Biosciences – PIPE – $175M – April 2026
Sagimet (Nasdaq: SGMT) priced 29,166,700 series A common shares at $6 on April 27, 2026, generating approximately $175M and closing April 28. This was a registered underwritten offering, not a private placement. The financing supports a pivot toward acne, led by oral FASN inhibitor denifanstat, following a China Phase 3 open-label study of 50 mg once-daily treatment in 240 patients that reported positive topline safety data. A US Phase 3 trial is planned for H2 2026, subject to IND clearance, while further MASH development requires non-dilutive financing. With $105M on March 31, the combined capital position is expected to fund acne programs through 2028.
Also check out Biopharma Therapeutics and Platforms Venture Funding – Q2 2026 Review
